TSHA in the 13F filings
Taysha Gene Therapies Inc · CUSIP 877619106
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 14 Nov 2025
- latest of these filings; the earliest 6 Nov 2025
- Managers listing it
- 2
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 1 listed it in both
- Shares listed
- 11,031,470
- combined, among listed positions
- Reported value
- $36m
- combined, at the quarter end
Among the 95 comparable managers: 1 buyer (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing TSHA in Q3 2025
2 of 2 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Point72 Asset Management LP | 7,331,470 | $24m | under 0.1% | Added | n.a. | 14 Nov 2025 (the filing on sec.gov) |
| Tybourne Capital Management HK Ltd | 3,700,000 | $12m | 39.11% | Trimmed | -395,000 | 6 Nov 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
- Tybourne Capital Management HK Ltdexisting position · 3,700,000 shares now-395,000
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2020 | 1 | $11m | n.a. | n.a. |
| Q4 2020 | 1 | $13m | n.a. | n.a. |
| Q1 2021 | 1 | $10m | n.a. | n.a. |
| Q2 2021 | 1 | $11m | n.a. | n.a. |
| Q3 2021 | 1 | $9.3m | n.a. | n.a. |
| Q4 2021 | 1 | $5.8m | n.a. | n.a. |
| Q1 2022 | 1 | $3.3m | n.a. | n.a. |
| Q2 2022 | 1 | $1.9m | n.a. | n.a. |
| Q3 2022 | 1 | $965k | n.a. | n.a. |
| Q4 2022 | 1 | $3.4m | n.a. | n.a. |
| Q1 2023 | 1 | $1.2m | n.a. | n.a. |
| Q2 2023 | 1 | $992k | n.a. | n.a. |
| Q3 2023 | 1 | $4.7m | n.a. | n.a. |
| Q4 2023 | 1 | $6.5m | 1 | 0 |
| Q1 2024 | 2 | $11m | 1 | 0 |
| Q2 2024 | 2 | $11m | 1 | 0 |
| Q3 2024 | 2 | $9.5m | 1 | 0 |
| Q4 2024 | 1 | $6.4m | 0 | 0 |
| Q1 2025 | 1 | $5.1m | 0 | 0 |
| Q2 2025 | 1 | $9.5m | 1 | 0 |
| Q3 2025 | 2 | $36m | 1 | 1 |
| Q4 2025 | 1 | $861k | 15 | 6 |
| Q1 2026 | 2 | $2.9m | 16 | 8 |
| Q2 2026 | 4 | $25m | 12 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TSHA and GILD →TSHA and AMGN →TSHA and ARGX →Choose a stock to compare with TSHA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TSHA, latest filings →Back to the 13F Explorer →